



LIGHTING UP CANCER CELLS



Empowering entrepreneurs
to crush cancer

IMPACT & PROGRESS REPORT **2025**



CHAIRMAN'S MESSAGE

Dear Madam, Dear Sir, Dear Friends of the Foundation,

The year 2025 was marked by a particularly complex economic environment for innovation in biotechnology. Start-ups are finding it increasingly difficult to secure the funding required to advance their discoveries. In this context, the role of a committed organisation such as our Foundation is more essential than ever. We remain convinced that supporting bold innovation is one of the most powerful levers to improve the future of patients suffering from cancer.

Nevertheless, there are genuine reasons for hope. **Major breakthroughs are opening new perspectives** for cancers where therapeutic options remain limited. Pancreatic cancer, one of the most formidable forms of the disease, is the subject of promising scientific advances. New therapeutic avenues are emerging, bringing hope that one day this cancer will no longer be synonymous with fatality.

Faced with this demanding context, the Foundation has redoubled its efforts. In 2025, we selected **two new laureates**, chosen for their transformative potential. We present them in the section "Our Promising Oncology Projects". These two innovative programmes share the ability to truly change the landscape of next-generation treatments and benefit thousands of patients.

We also provided **additional funding to the projects "Chasing the Clouds" and "Light the Fire"**, enabling their entry into clinical trials in 2026 as initially planned — because in this fight, every month counts for patients.

In 2025, thanks to your generosity, we raised **€510,000** to support the **"Light the Fire"** project led by Hephaistos Pharma. This innovative therapy transforms "cold" tumours, invisible to the immune system, into "hot" tumours that our defences can then attack, offering tangible hope for young patients suffering from osteosarcoma and, soon, for triple-negative breast cancer.

In 2026, the funds raised will primarily support our new project:

"Domino Effect". It develops an innovative molecule that blocks a key enzyme in cancer cells, triggering their self-destruction and activating the immune system to eliminate them - a promising **dual action against resistant melanomas and colorectal cancers**.

These achievements would not have been possible without you. Your generosity is the driving force behind these advances, whether through your donations, your presence at our gala evening, your participation in the 20 km of Brussels, or your personal challenges - sporting, *in memoriam*, or any other heartfelt initiative.

Each of these gestures, large or small, contributes to a **ripple effect** that helps move science closer to patients. Together, let us continue to turn hope into reality.

With my deepest gratitude,

Jérôme Majoie

Chairman

OUR IMPACT MEASURED IN 2025

6

ACTIVE
PROJECTS

589

GENEROUS
DONORS

€ 510 K

RAISED TO
SUPPORT
SCIENTIFIC
PROJECTS

SINCE OUR CREATION

200

JOB'S CREATED
WITHIN OUR
LAUREATES'
TEAMS

328

PROJECTS
ANALYSED AND
REVIEWED

23

PROJECTS
SUPPORTED

42

PATENTS
FILED

MORE THAN € 15M
ALLOCATED
TO RESEARCH
PROJECTS

OUR MISSION :

TO SAVE LIVES,
WE IDENTIFY, FUND AND
SUPPORT RESEARCHERS SO
THAT THEIR SCIENTIFIC
DISCOVERIES BENEFIT
PEOPLE SUFFERING FROM
CANCER.



CANCER, A GLOBAL SCOURGE

Today, cancer still kills **1 in 2** people.

Behind this stark figure lie millions of disrupted lives: children, women and men confronted with the disease, families whose daily lives are turned upside down, life paths cut short far too soon.

Globally, **more than 10 million people die from cancer each year**. Cancer therefore remains one of the greatest public health challenges of our time.


Yet the situation has changed profoundly. Fifty years ago, 3 out of 4 patients did not survive cancer. Thanks to scientific advances, treatments have multiplied, improved and become more personalised, saving millions of lives.

These advances demonstrate the decisive impact of research.

But 1 death in 2 remains unacceptable. It highlights the scale of the journey still ahead to better prevent, diagnose and treat the disease.

One key lever remains essential to change the game: **scientific research**. It is research that will make it possible to improve existing treatments, develop ever earlier diagnostics and create the therapies of tomorrow.

So that, one day, **surviving cancer becomes the rule - not the exception.**





At the age of 27, **Bernard Majoie**, Doctor of Pharmacy, seized the opportunity to develop a pharmaceutical R&D department within Laboratoires Fournier. Gradually, he would transform this family business of 400 people into a global company employing more than 4,000 people.

Building on this success and driven by a desire **to give back**, he created the Fournier-Majoie Foundation in 2007.

His aim : to help researchers become entrepreneurs against cancer, so that their scientific discoveries can contribute to defeating this devastating disease.

Indeed, throughout his entrepreneurial journey, **Bernard** Majoie observed that many promising cancer research projects never reached patients due to a lack of adequate financial and managerial support.

On the occasion of the Foundation's 10th anniversary in 2017, Bernard Majoie handed over to his son Jérôme. Bernard Majoie passed away in December 2021, leaving behind a lasting philanthropic legacy within the Foundation through the many promising projects it supports.




OUR MOMENT OF INTERVENTION

Everything begins in a **laboratory**, where a researcher and their team make a promising discovery.

A **patent** is then filed and hypotheses are developed to transform or improve this discovery into a therapeutic solution.

They must then provide **proof of concept demonstrating**:

- its mechanism of action in the body
- its effectiveness
- its tolerability
- and how it can be produced at scale in a stable manner



THE FOUNDATION SUPPORTS RESEARCHERS AT A CRUCIAL MOMENT

It is at this pivotal stage, just after proof of concept, that the Fournier-Majoie Foundation has chosen to intervene.

It provides both **financial resources AND entrepreneurial support** to researchers to facilitate the success of preclinical phases and prepare entry into clinical phases (those involving the first patients).

We then hand over to other stakeholders (investors or industry players) with a partially de-risked project that offers genuine medical prospects.

7 THE FOUNDATION'S TRIPLE SUPPORT

It is not always easy for a researcher to step into the role of entrepreneur and secure funding to support their project. They must overcome a real **obstacle course** to ensure their innovative therapeutic solution reaches patients.

To maximise the chances of success, the Foundation conducts a **rigorous analysis of promising oncology projects** that could bring tangible medical advances across various cancers: ovarian, colorectal, breast, kidney, stomach, blood, bone cancers and many others.

The Foundation's rigorous analysis is based on 14 scientific, commercial and financial criteria.

**Once selected,
the Foundation
offers its laureates:**

1

Financial support of up to €2.5 million per project, at a stage where investors are generally reluctant

2

Genuine **entrepreneurial support** through a wide network of scientific, technical, financial and business experts

3

Access to a network of private and public investors as part of fundraising efforts



WHAT MAKES THE FOUNDATION UNIQUE ?

1 | **100% MODEL:** MAXIMISING THE IMPACT OF YOUR GENEROSITY

All donations are allocated directly and exclusively to cancer research projects — this is our commitment.

All of the Foundation's operating costs are covered by a separate endowment from our founder, Bernard Majoie.

2 | **"PHILANTHROPRENEURS"** A HYBRID CONCEPT COMBINING PHILANTHROPY AND ENTREPRENEURSHIP

Philanthropy, because we combine altruism, absence of personal enrichment, and commitment.

Entrepreneurship, because our support consists in equipping and advising project leaders in their entrepreneurial journey, in order to limit risks as much as possible and measure both impact and project potential.

"Philanthropreneurs" embody this new approach to philanthropy, focused on efficiency and impact, inspired by the business world.



3 | A DNA CLOSE TO BUSINESS LEADERS

Our entrepreneurial spirit is clearly reflected in our vision: “empowering entrepreneurs to crush cancer”, as well as in a series of characteristics that business leaders will immediately identify with:

1. Strong **ambition**, aiming to deliver new therapeutic solutions
2. A (measured) **risk-taking** approach, by committing our capital after rigorous project selection
3. A constant focus on **impact**, contributing to saving lives and creating jobs (200 jobs created within our laureates' teams)

4 | THE VIRTUOUS CIRCLE

Aware of the opportunities he had been given to become an entrepreneur and achieve success, our founder Bernard Majoie was keen to “**give back**”. This philosophy remains one of the driving forces behind our actions.

Each laureate who benefits from the Foundation's support commits to helping future researchers if their initiative succeeds.

From being supported, they **become supporters in turn**, contributing to a virtuous circle that defines the Foundation.

The donations we receive therefore become **sustainable**: they support not just one project, but several successive ones.

A concrete example of the virtuous cycle: MABLINK Bioscience:

When the Foundation supported the project nicknamed “the Invisibility Cloak” and its PSARlink technology in its early stages, it was still a lab concept. This early boost enabled the project to be taken on by Eli Lilly for large-scale development. Today, following encouraging results, more than 100 patients with advanced ovarian cancer are benefiting from it as part of a Phase II-III clinical trial.



OUR MEASURED IMPACT

1 HEALTH IMPACT

- Each supported project aims to develop new cancer treatments
- Some projects also aim to improve patients' quality of life
- Research supported by the Foundation is already benefiting several **hundred patients**

2 MULTIPLIED IMPACT

€1 invested generates €8

This multiplier effect is achieved through a combination of:

- tax deductibility of donations
- strong leverage to secure public funding
- mobilisation of additional private funding thanks to the Foundation's reputation and commitment

3 ECONOMIC IMPACT

The support and guidance provided by the Foundation have helped, and continue to help, our laureates succeed in their entrepreneurial journey.

Thanks to our commitment, our laureates have created 200 jobs to date.

4 SUSTAINABLE IMPACT

With our **"give-back"** approach, beneficiaries become supporters, activating a genuine virtuous circle.

Support for a successful project is returned to the Foundation to help fund and support new projects. In this way, a single donation can support several successive projects.



THE BUTTERFLY EFFECT TO SAVE LIVES

The butterfly effect lies at the heart of our mission and symbolises the powerful idea that every small gesture, every act of solidarity — when combined — can have **extraordinary consequences** for those courageously fighting the disease.

If all the projects currently supported by the Foundation were to succeed, they could have a positive impact on

7.2 million people.

Each supported project represents a glimmer of hope for patients awaiting treatment.

Just as every donation represents one more step towards a future without cancer.



OUR PROMISING ONCOLOGY PROJECTS

FOCUS PROJECT 2025 - LIGHT THE FIRE

TARGETED CANCERS: OSTEOSARCOMAS, LYMPHOMAS, COLORECTAL, PANCREATIC AND TRIPLE-NEGATIVE BREAST CANCERS

The Foundation supports the development of an immune stimulant whose initial results show very promising cure rates, particularly for cancers that currently lack effective treatments.

ONCO-Boost transforms "cold" tumours into "hot" tumours, making them visible to immune cells, which can then destroy them.

The therapy will first be developed as a monotherapy for osteosarcoma (a bone cancer primarily affecting 12–20-year-olds), before being combined with existing immunotherapies to improve their effectiveness against other cancers.

Advantages compared to existing molecules

- Soluble and low toxicity
- Administered intravenously
- Improved therapeutic index (the minimum effective dose without adverse effects)

Major advances in 2025

- In preclinical **osteosarcoma** tests, the molecule used as a monotherapy achieved a **78% complete cure rate**
- Positive results in **triple-negative breast cancer** and **B-cell lymphoma**
- Transfer of the process to a specialised partner (CDMO), a key step towards large-scale production
- Ongoing studies to identify priority cancers

IN 2026, THANKS TO YOUR GENEROSITY, €510,000 WAS RAISED TO SUPPORT THIS PROJECT

How will your generosity be used?

To enter the clinical phase, ONCO-Boost production must meet high-quality standards, with a total budget exceeding €3 million. In parallel, approximately €35,000 per patient is required to cover hospital costs for early clinical phases. The objective is to treat the first patients from 2027.



Frédéric Caroff



DOMINO EFFECT


TARGETED CANCERS: SKIN CANCERS (STAGE III AND IV MELANOMAS), RESISTANT COLORECTAL CANCERS

Then potentially other solid tumours

Our project leaders are developing a treatment that blocks the enzyme ELP3, which is crucial for the growth and resistance of cancer cells.

Its action produces a dual effect:

- self-destruction of tumour cells
- activation of the immune system to eliminate them



To grow and resist treatment, cancer cells produce large quantities of specific proteins and the ELP3 enzyme plays a central role in this.

Cancer stem cells, responsible for relapses, rely heavily on it to evade the immune system and resist therapies.

DOMINO EFFECT 1 : blocking ELP3 disrupts protein production, weakening cancer cells until they self-destruct.

DOMINO EFFECT 2: This disruption forces cancer cells to emit signals, attracting immune “soldiers” (T lymphocytes and NK cells) which then attack and eliminate them.

Initially, the molecule will be developed for **melanomas** to determine the optimal dose, before targeting **colorectal cancers**, where relapse rates reach 30–40% within three years.



Francesca Rapino
and Pierre Close

THERATAME



Michael Lukesch,
CEO VALANX
Biotech GmbH



HIGH ANTI-CANCER JEWELLERY

TARGET CANCERS: breast cancers that are particularly difficult to treat

Then extended to other cancers

Like a jeweller who sets each stone with meticulous care, our project lead is crafting a new generation of ADCs, targeted anti-cancer therapies designed to eliminate cancer cells whilst preserving healthy cells.

ADCs use guided missiles to transport powerful active agents directly to cancer cells. But if these active agents are poorly attached, they can detach before reaching their target and damage healthy cells.

Just as perfectly set gemstones reveal the full splendour of a piece of jewellery, the solution developed by our laureate relies on an **ultra-precise manufacturing method that firmly anchors** the active agents to the missile, like perfectly set gemstones revealing the full power of the jewellery.

Benefit #1: reduced toxicity. The toxins remain attached to the missile throughout their journey through the body, without damaging healthy cells.

Benefit #2 : greater efficacy. This secure delivery system allows higher doses to be used, increasing efficacy against the targeted cancer cells.

Benefit #3 : greater innovation. These improvements pave the way for novel combinations of several complementary active agents on a single missile.

Already used against several cancers (breast, bladder, lung, ovary), ADCs will see this technology applied primarily to certain hard-to-treat **breast cancers**, with the **potential to extend** to many other cancers. By improving the safety of ADCs, we will broaden the spectrum of treatable cancers.

CHASING THE CLOUDS

**TARGETED CANCERS:
OVARIAN AND COLORECTAL,
TRIPLE-NEGATIVE BREAST**

Cancer's primary enemy is our immune system, which is responsible for destroying abnormal cells in our body. However, certain cancers -notably **colorectal and ovarian**- produce a protein (TSP-1) that forms a "cloud" around the tumour, rendering the immune system ineffective.

Dr Albin Jeanne and his team (Apmonia Therapeutics) have developed **TAX2**, an immunotherapy that targets TSP-1 to "**chase the clouds**" and enable the immune system to eliminate cancer cells.

In 2025, an application for authorisation of a Phase I/IIa clinical trial was submitted for patients with advanced solid tumours. Other products targeting cathepsin-D (a protein that promotes tumour spread) are in development, notably for **triple-negative breast cancer**.

At the same time, the company has secured € 10 million in funding and established an R&D subsidiary in Liège.



Dr. Albin Jeanne, research scientist and manager, co-founder of Apmonia Therapeutics

 **APMONIA
THERAPEUTICS**

TOBACCO TO TREAT CANCER

**TARGETED CANCERS: NON-HODGKING'S
LYMPHOMA** and potentially solid tumours

Could you ever have imagined that tobacco might one day cure cancer?

This is what Dr Bertrand Magy, Max Houry and their team, based near Marche-en-Famenne, are in the process of demonstrating. They have developed a new class of drugs derived **from tobacco plants: atbodies all-in-one** anti-cancer missiles combining a homing device and active agents to destroy cancer cells. This therapy is proving to be **very powerful, highly targeted** (particularly for **blood cancers**) and **twice as quick** to produce as traditional therapies.

Building on these advances, ATB Therapeutics raised 54 million in 2024 to accelerate the development of treatments for cancer and autoimmune diseases, enhanced its ATBioFarm platform and created innovative therapeutic antibodies. A laboratory was opened in Ghent, doubling the workforce, whilst a new manufacturing facility is under construction in Marche-en-Famenne.



Dr. Bertrand Magy

 **atbtherapeutics**

BOARD OF DIRECTORS

People committed and dedicated to fulfilling our mission

Our Foundation has been chaired by Jérôme Majoie since 2017.

The Board of Directors comprises six members.

All serve in a pro bono capacity.

Jérôme Majoie,

Chairman and Chief Executive Officer of the Fournier-Majoie Foundation

François Charlet,

Managing Partner of Intuitae Switzerland

Rudy Dekeyser,

Managing Partner of LSP Health Economics Funds

Jacques Mallet,

Chairman and CEO of Gamma-X Corporate Advisory

Paul Van Dun,

Director General of the R&D Department at KU Leuven

SCIENTIFIC AND INVESTMENT ADVISORY BOARD

To fulfil its mission, the Foundation relies on its Scientific and Investment Advisory Board, which interviews project leaders to assess, first and foremost, the soundness and relevance of the scientific innovation.

This multidisciplinary Board comprises experts in oncology and biostatistics, industry practitioners in clinical development, and investment fund managers. It ensures that the selected projects meet scientific, commercial and financial criteria and are likely to provide effective, innovative solutions to current oncological challenges.

All these advisors contribute pro bono to the evaluation and monitoring of projects.

Dr Vincent Brichard

Professor Marc Buyse

Dr Rudy Dekeyser

Professor Ferdinand Lejeune

Dr Jacques Mallet

Professor Bart Neyns

Mr Jan Pensaert

Mr Paul Van Dun

OPERATIONAL TEAM

On a day-to-day basis, the Foundation is managed by a team comprising **Jérôme Majoie** (Chairman and Chief Executive Officer), **Mathilde Jooris** (Philanthropy), **Coralie Lion** (Communications), **Natalia Cechagias** (Finance and Administration) and **Serge Schmitz** (Fundraising Strategy and Communications).

Jérôme Majoie can also count on the expertise of **Ana Maricevic** for competitiveness analyses and **Dr Peter De Waele** for scientific matters and issues relating to intellectual property.



THE 2025 HONORARY COMMITTEE

The role of our **Ambassadors** is to promote the Foundation's name and mission throughout the year.

Together with the **Support Committee**, they are also particularly active in the preparation and organisation of our events, such as the Brussels 20KM or the Gala Evening, notably through their ideas, advice, extensive contacts and fundraising efforts.

They all carry out their duties with enthusiasm and on a voluntary basis.

AMBASSADORS

Jean-Cédric van der Belen
Sarina de Ganay
Stéphane d'Udekem d'Acoz
Virginie Vaxelaire

SUPPORT COMMITTEE

Hubert de Biolley
John-Alexander Bogaerts
Anne-Sophie Charle
Jennifer Gobiet
Gwenaële de Meulemeester
Vinciane Morel de Westgaver
Delphine Remy
Philippe de Selliers de Moranville
Sébastien Ulens

KEY EVENTS IN 2025

SUPPORTING THE FOURNIER-MAJOIE FOUNDATION THROUGH ITS EVENTS MEANS FIGHTING TOGETHER AGAINST THE GLOBAL SCOURGE OF CANCER.

20 KM OF BRUSSELS

“Run to burn cancer” - MAY 2025

THE legendary event bringing together thousands of athletes in the capital. Thank you to everyone who set the streets of Brussels alight in the fight against cancer, and to all the supporters who fuelled this flame of hope through their generosity.



GALA EVENING

« Light the fire » - OCTOBER 2025

Every year, the Fournier-Majoie Foundation organises a **prestigious dinner** followed by a **dance** at an exceptional venue. In 2025, “Light the fire” was the theme of a dazzling and vibrant evening in support of cancer research. Our guests, carried along by infectious energy, lit up the night with their generosity and commitment to the Foundation.




LARISSA ICKX CHARITY AUCTION

JUNE 2025

When art supports research.

To mark her move, artist Larissa Ickx opened the doors of her studio to organise a charity sale in aid of the Fournier-Majoie Foundation. Thank you to Larissa for her commitment to the fight against cancer, and to everyone who chose to purchase a work imbued with meaning and hope.





LES VOILES DU ZOUTE

SEPTEMBER 2025

For the fourth consecutive year, the Foundation was the charitable partner of the inter-company regatta "Les Voiles du Zoute", which took place in the famous seaside resort of Knokke-Heist. In ideal weather conditions, sport, conviviality and professional networking came together in support of cancer research.

Belgian artist **Denis Meyers** lit up the day with a live performance and customisable canvases, conveying hope in the fight against the disease.



"IT IS MAJOIE TO INVITE YOU" DINNERS

The idea behind these charity dinners is to ask guests to come empty-handed (no wine, flowers, chocolates, etc.) and instead make a donation to support the fight against cancer in a different way.

The aim is for one of the guests to take up the baton to create a chain of dinners in aid of the Foundation.



CRAZY CHALLENGES

Whether on your own, with family, friends or colleagues, the aim of the Crazy Challenges is to set yourself a challenge whilst rallying those around you to support cancer research.

Thank you to Stéphane, who ran 500 km, and to Mathilde, who walked 35 km a day for 17 consecutive days (a total of 600 km) along the GR34 to bring hope to those affected by the disease.

HOW CAN YOU SUPPORT US ?



ANNE-SOPHIE AND HUBERT EWBank DE WESPIN

CEO MAISON EOLE - CEO CHANT D'EOLE

"We provide well-being through our bubbles and our cosmetics. Products that we share and that bring people together. When all is well. For those who are suffering, well-being means adding life to days rather than days to life. Committing to the Fournier-Majoie Foundation means becoming a link in this chain of solidarity against cancer. The disease that affects us all in our family and social circles. The one that gnaws away at us but which, fortunately, often strengthens our resilience. It is our responsibility to invest in research. To add life to life tomorrow."

PARTNER COMPANY

As a business, you have the opportunity to help save lives by supporting scientific research. Reap the benefits of positive outcomes by engaging in a philanthropic initiative that addresses a major societal challenge.

Become a corporate partner of the Fournier-Majoie Foundation

- by encouraging your staff to get involved and support the cause and the Foundation
- by donating a portion of the proceeds from the sale of your products/ services to the Foundation
- by providing products or services
- by sponsoring our events

**Contact us : philanthropreneur@fournier-majoie.org
Tel : +32 2 370 47 23**

Thank you to our partners:

Artfood Traiteur, Chant d'Eole, Event Lounge, Gabriel Lelievre, Gillion Construct, GSP2, Intesa Sanpaolo Wealth Management, Julius Bär, LDV production, Leopold Café Presse, Leonidas, Louis-Henri Vienne, Maison Eole, Puressentiel, Rothschild & Co Wealth Management Belgium, Voiles du Zoute, WMH

And to our generous in-kind donors:

Axelle Delhaye, Fondation CAB, Gauthier Van Reepinghen, Geneviève Lemal, Hubert et Anne Sophie Ewbank de Wespin, L'Hôtel Les Lumières Versailles, La Fondation Boghossian, Le Beau Rivage, Les Maisons CAB, L'Opéra Royal du Château de Versailles, Philippe Saveurs, Rodrigue Gillion, Rothschild & Co Wealth Management

By supporting our promising scientific projects, you bring a ray of hope to those suffering from cancer.

Your generosity can be tax-efficient and make a real difference to people's lives.

DONATE

- Make a tax-deductible donation
- Include the Foundation in your will
- Shop online via Trooper (www.trooper.be)

RAISE FUNDS

- Organise a « C'est Majoie de vous inviter » dinner
- Create your own Crazy Challenge
- Celebrate a personal occasion (birthday, wedding, birth, etc.)
- Honour the memory of a loved one

TAKE PART

- Run or walk the 20 km of Brussels
- Join our Gala Evening





THANK YOU

Thank you from the bottom of our hearts for your generosity!

22

- To our donors
- To our Ambassadors and our Support Committee
- To our partners and companies who actively supported us in 2025
- To the artists and public figures who supported our cause in 2025:

SERGE ANTON, JEAN BOGHOSSIAN, AXELLE DELHAYE, GÉRALD DE PATOUL, LARISSA ICKX, CHARLES KAISIN, CURTIS MAQUET, DENIS MEYERS, MIREILLE ROOBAERT, MAGALIE VAÉ

MAKE A DONATION

IF YOU ARE NOT A BELGIAN RESIDENT OR DO NOT REQUIRE A TAX CERTIFICATE

You can make a donation directly

Account : Fournier-Majoie Foundation

IBAN : BE02 0020 2384 1140

BIC : GEBABEBB

Reference : Impact Report

You too can become a Philanthropreneur by supporting cancer research

IF YOU ARE A BELGIAN RESIDENT

By making a donation of at least €40 during the calendar year, you can benefit from a tax advantage.

Account : King Baudouin Foundation / FFM

IBAN : BE10 0000 0000 0404

BIC : BPOTBEB1

Reference : +++197/0370/00076+++
(important to mention)

SCAN TO MAKE
A DONATION



www.fournier-majoie.org

Avenue de Fré 269 / B 44 - 1180 Brussels - Belgium

Email: philanthropreneur@fournier-majoie.org Tel: +32 2 370 47 25